Haruki S.,Tsuchiura General Kyodo Hospital |
Takiguchi N.,Tsuchiura General Kyodo Hospital |
Arita K.,Tsuchiura General Kyodo Hospital |
Usui S.,Tsuchiura General Kyodo Hospital |
And 4 more authors.
Japanese Journal of Cancer and Chemotherapy | Year: 2013
We have no consensus on surgical treatment and chemotherapy for esophagogastric junction cancer in Japan. A 51-year-old man reporting dysphagia was examined, and through upper gastrointestinal endoscopy was found to have a tumor at the esophagogastric junction. Histologically, biopsy specimens indicated adenocarcinoma with genetic amplification of human epidermal growth factor receptor type 2 (HER2). Positron emission tomography showed swelling of several abdominal lymph nodes with accumulation of fluorodeoxyglucose. He was treated with esophagogastorectomy with left thoracotomy after combination chemotherapy of docetaxel, cisplatin, S-1, and trastuzumab. He had no complication from the operation and had no adverse effect from the combination chemotherapy. Histopathological examination of the resected specimen showed a minute residual cancer nest at the muscularis propria of the esophagus, but no lymph node metastasis. This regimen could be useful for advanced junctional cancer with HER2 amplification as preoperative chemotherapy.